Table 4 Correlation between ER positivity and major clinical responses (CR+PR) to therapy

From: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

Responses

ER positive (27/41 patients)

ER negative (14/41 patients)

CR+PR (22/41 patients)

19/27 patients (70%)

3/14 patients (21%)

SD+PD (19/41 patients)

8/27 patients (30%)

11/14 patients (79%)

  1. Pearson's χ2 test: P=0.01.
Back to article page